Cargando…

Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA)

INTRODUCTION: The UK has worse cancer outcomes than most comparable countries, with a large contribution attributed to diagnostic delay. Electronic risk assessment tools (eRATs) have been developed to identify primary care patients with a ≥2% risk of cancer using features recorded in the electronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamilton, Willie, Mounce, Luke, Abel, Gary A, Dean, Sarah Gerard, Campbell, John L, Warren, Fiona C, Spencer, Anne, Medina-Lara, Antonieta, Pitt, Martin, Shephard, Elizabeth, Shakespeare, Marijke, Fletcher, Emily, Mercer, Adrian, Calitri, Raff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030284/
https://www.ncbi.nlm.nih.gov/pubmed/36940950
http://dx.doi.org/10.1136/bmjopen-2022-065232
_version_ 1784910327663558656
author Hamilton, Willie
Mounce, Luke
Abel, Gary A
Dean, Sarah Gerard
Campbell, John L
Warren, Fiona C
Spencer, Anne
Medina-Lara, Antonieta
Pitt, Martin
Shephard, Elizabeth
Shakespeare, Marijke
Fletcher, Emily
Mercer, Adrian
Calitri, Raff
author_facet Hamilton, Willie
Mounce, Luke
Abel, Gary A
Dean, Sarah Gerard
Campbell, John L
Warren, Fiona C
Spencer, Anne
Medina-Lara, Antonieta
Pitt, Martin
Shephard, Elizabeth
Shakespeare, Marijke
Fletcher, Emily
Mercer, Adrian
Calitri, Raff
author_sort Hamilton, Willie
collection PubMed
description INTRODUCTION: The UK has worse cancer outcomes than most comparable countries, with a large contribution attributed to diagnostic delay. Electronic risk assessment tools (eRATs) have been developed to identify primary care patients with a ≥2% risk of cancer using features recorded in the electronic record. METHODS AND ANALYSIS: This is a pragmatic cluster randomised controlled trial in English primary care. Individual general practices will be randomised in a 1:1 ratio to intervention (provision of eRATs for six common cancer sites) or to usual care. The primary outcome is cancer stage at diagnosis, dichotomised to stage 1 or 2 (early) or stage 3 or 4 (advanced) for these six cancers, assessed from National Cancer Registry data. Secondary outcomes include stage at diagnosis for a further six cancers without eRATs, use of urgent referral cancer pathways, total practice cancer diagnoses, routes to cancer diagnosis and 30-day and 1-year cancer survival. Economic and process evaluations will be performed along with service delivery modelling. The primary analysis explores the proportion of patients with early-stage cancer at diagnosis. The sample size calculation used an OR of 0.8 for a cancer being diagnosed at an advanced stage in the intervention arm compared with the control arm, equating to an absolute reduction of 4.8% as an incidence-weighted figure across the six cancers. This requires 530 practices overall, with the intervention active from April 2022 for 2 years. ETHICS AND DISSEMINATION: The trial has approval from London City and East Research Ethics Committee, reference number 19/LO/0615; protocol version 5.0, 9 May 2022. It is sponsored by the University of Exeter. Dissemination will be by journal publication, conferences, use of appropriate social media and direct sharing with cancer policymakers. TRIAL REGISTRATION NUMBER: ISRCTN22560297.
format Online
Article
Text
id pubmed-10030284
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100302842023-03-22 Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA) Hamilton, Willie Mounce, Luke Abel, Gary A Dean, Sarah Gerard Campbell, John L Warren, Fiona C Spencer, Anne Medina-Lara, Antonieta Pitt, Martin Shephard, Elizabeth Shakespeare, Marijke Fletcher, Emily Mercer, Adrian Calitri, Raff BMJ Open General practice / Family practice INTRODUCTION: The UK has worse cancer outcomes than most comparable countries, with a large contribution attributed to diagnostic delay. Electronic risk assessment tools (eRATs) have been developed to identify primary care patients with a ≥2% risk of cancer using features recorded in the electronic record. METHODS AND ANALYSIS: This is a pragmatic cluster randomised controlled trial in English primary care. Individual general practices will be randomised in a 1:1 ratio to intervention (provision of eRATs for six common cancer sites) or to usual care. The primary outcome is cancer stage at diagnosis, dichotomised to stage 1 or 2 (early) or stage 3 or 4 (advanced) for these six cancers, assessed from National Cancer Registry data. Secondary outcomes include stage at diagnosis for a further six cancers without eRATs, use of urgent referral cancer pathways, total practice cancer diagnoses, routes to cancer diagnosis and 30-day and 1-year cancer survival. Economic and process evaluations will be performed along with service delivery modelling. The primary analysis explores the proportion of patients with early-stage cancer at diagnosis. The sample size calculation used an OR of 0.8 for a cancer being diagnosed at an advanced stage in the intervention arm compared with the control arm, equating to an absolute reduction of 4.8% as an incidence-weighted figure across the six cancers. This requires 530 practices overall, with the intervention active from April 2022 for 2 years. ETHICS AND DISSEMINATION: The trial has approval from London City and East Research Ethics Committee, reference number 19/LO/0615; protocol version 5.0, 9 May 2022. It is sponsored by the University of Exeter. Dissemination will be by journal publication, conferences, use of appropriate social media and direct sharing with cancer policymakers. TRIAL REGISTRATION NUMBER: ISRCTN22560297. BMJ Publishing Group 2023-03-20 /pmc/articles/PMC10030284/ /pubmed/36940950 http://dx.doi.org/10.1136/bmjopen-2022-065232 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle General practice / Family practice
Hamilton, Willie
Mounce, Luke
Abel, Gary A
Dean, Sarah Gerard
Campbell, John L
Warren, Fiona C
Spencer, Anne
Medina-Lara, Antonieta
Pitt, Martin
Shephard, Elizabeth
Shakespeare, Marijke
Fletcher, Emily
Mercer, Adrian
Calitri, Raff
Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA)
title Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA)
title_full Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA)
title_fullStr Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA)
title_full_unstemmed Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA)
title_short Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA)
title_sort protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of electronic risk-assessment for cancer for patients in general practice (erica)
topic General practice / Family practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030284/
https://www.ncbi.nlm.nih.gov/pubmed/36940950
http://dx.doi.org/10.1136/bmjopen-2022-065232
work_keys_str_mv AT hamiltonwillie protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT mounceluke protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT abelgarya protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT deansarahgerard protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT campbelljohnl protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT warrenfionac protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT spenceranne protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT medinalaraantonieta protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT pittmartin protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT shephardelizabeth protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT shakespearemarijke protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT fletcheremily protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT merceradrian protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica
AT calitriraff protocolforapragmaticclusterrandomisedcontrolledtrialassessingtheclinicaleffectivenessandcosteffectivenessofelectronicriskassessmentforcancerforpatientsingeneralpracticeerica